$AUPH With Big Pharma no longer (not for many years now) the seat of innovation, with access to cheap financing and with a major need to replace revenues lost from patent expiries, it's a sellers market for biopharma 'targets'. The Betaville article suggested that Aurinia is in discussion with a number of different BP players... this could easily account for the process taking longer than some had thought but will ultimately be worth the wait. If anyone on this thread is from the Toronto or Vancouver areas and been a seller or real estate in recent years, you'll profoundly understand the benefits of having 'multiple offers' :) fiercepharma.com/pharma/mer...